OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,192.17% | 10.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,192.17% | 10.58% | |||
| Cost of Revenue | 1,920.93% | 34.38% | |||
| Gross Profit | 756.94% | 0.00% | |||
| SG&A Expenses | 4.24% | 10.67% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.46% | 12.54% | |||
| Operating Income | 14.93% | -12.57% | |||
| Income Before Tax | -148.36% | -197.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -148.36% | -197.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -148.36% | -197.86% | |||
| EBIT | 14.93% | -12.57% | |||
| EBITDA | 19.47% | -13.08% | |||
| EPS Basic | -95.94% | -176.07% | |||
| Normalized Basic EPS | 34.09% | -7.18% | |||
| EPS Diluted | -95.94% | -176.07% | |||
| Normalized Diluted EPS | 34.09% | -7.18% | |||
| Average Basic Shares Outstanding | 26.75% | 6.56% | |||
| Average Diluted Shares Outstanding | 26.75% | 6.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||